Stabilized formulations of lipid nanoparticles

Patent metadata

Field	Value
Publication number	US-12144895-B2
Application number	US-202218065368-A
Country	US
Kind code	B2
Filing date	Dec 13, 2022
Priority date	Nov 8, 2016
Publication date	Nov 19, 2024
Grant date	Nov 19, 2024

Abstract

The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof. Lipid nanoparticles further including therapeutics and/or prophylactics such as RNA are useful in the delivery of therapeutics and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. Methods of manufacturing LNP formulations and screening for a stabilizing agent are also disclosed.

First claim

The invention claimed is:

1. A lipid nanoparticle (LNP) formulation, comprising a plurality of LNPs and a stabilizing agent, wherein the stabilizing agent comprises a cryoprotectant and an antioxidant.

2. The LNP formulation of claim 1 , wherein an antioxidant is citric acid.

3. The LNP formulation of claim 2 , wherein the cryoprotectant is a polyol, a nondetergent sulfobetaine, an osmolyte, a PEG, a polyvinylpyrrolidone, pentaerythritol propoxylate, or polypropylene glycol P 400, an organic solvent, a sugar, or a salt.

4. The LNP formulation of claim 2 , wherein the cryoprotectant is:
i) glycerol;
ii) propylene glycol;
iii) glycerol and sucrose; or
iv) glycerol and ethanol.

5. The LNP formulation of claim 4 , wherein the cryoprotectant is:
i) glycerol;
ii) glycerol and sucrose; or
iii) glycerol and ethanol.

6. The LNP formulation of claim 4 , wherein the concentration of glycerol in the formulation ranges from about 1 mM to about 10 M, from about 5 mM to about 5 M, from about 10 mM to about 1 M, from about 50 mM to about 600 mM, from about 100 mM to about 500 mM, or from about 200 mM to about 300 mM, or wherein the concentration of glycerol in the formulation is about 250 mM.

7. The LNP formulation of claim 4 , wherein the concentration of propylene glycol in the formulation ranges from about 1 mM to about 10 M, from about 5 mM to about 5 M, from about 10 mM to about 1 M, from about 50 mM to about 600 mM, from about 100 mM to about 500 mM, or from about 200 mM to about 300 mM, or wherein the concentration of propylene glycol in the formulation is about 250 mM.

8. The LNP formulation of claim 4 , wherein the concentration of sucrose in the formulation ranges from about 1 mM to about 10 M, from about 5 mM to about 5 M, from about 10 mM to about 1 M, from about 50 mM to about 600 mM, from about 100 mM to about 500 mM, or from about 200 mM to about 300 mM, or wherein the concentration of sucrose in the formulation is about 250 mM.

9. The LNP formulation of claim 4 , wherein the molar ratio of glycerol and sucrose in the formulation ranges from about 1:100 to about 100:1, from about 1:50 to about 50:1, from about 25:1 to about 1:25, from about 10:1 to about 1:10, from about 5:1 to about 1:5, or from about 2:1 to about 1:2.

10. The LNP formulation of claim 4 , wherein the molar ratio of glycerol and ethanol in the formulation ranges from about 1:100 to about 100:1, from about 1:50 to about 50:1, from about 25:1 to about 1:25, from about 10:1 to about 1:10, from about 5:1 to about 1:5, or from about 2:1 to about 1:2 or wherein the molar ratio of glycerol and ethanol in the formulation is about 1:1.

11. The LNP formulation of claim 4 , wherein the stabilizing agent further comprises a nonionic surfactant.

12. The LNP formulation of claim 11 , wherein the nonionic surfactant is a polysorbate.

13. The LNP formulation of claim 12 , wherein the polysorbate has a structure of Formula (IV):

wherein the sum of w, x, y, and z ranges from about 0 to about 200, about 0 to about 100, from about 10 to about 90, or from about 20 to about 80; or wherein the sum of w, x, y, and z is about 20, about 40, about 60, or about 80.

14. The LNP formulation of claim 12 , wherein the polysorbate is polysorbate 20, polysorbate 40, polysorbate, 60, or polysorbate 80.

15. The LNP formulation of claim 14 , wherein the concentration of polysorbate 20 ranges from about 0.0001% w/v to about 1.0% w/v, from about 0.001% w/v to about 0.1% w/v, from about 0.005% w/v to about 0.05% w/v, from about 0.008% w/v to about 0.03% w/v, or from about 0.009% w/v to about 0.02% w/v, or wherein the concentration of polysorbate 20 is about 0.01% w/v.

16. The LNP formulation of claim 4 , wherein the LNPs further comprise an ionizable lipid and a structural lipid.

17. The LNP formulation of claim 16 , wherein the LNPs further comprise a PEG lipid.

18. The LNP formulation of claim 1 , wherein the pH value of the formulation ranges from about 4 to about 11, from about 5 to about 10, from about 6 to about 9, from about 7 to about 8, or from about 7.3 to about 7.5, or wherein the pH value of the formulation is about 7.4.

19. The LNP formulation of claim 1 , wherein the stabilizing agent further comprises a chelator, wherein the chelator comprises diethylenetriamine pentaacetic acid (DTPA), ethylenediaminetetraacetic acid (EDTA), iminodisuccinic acid, polyaspartic acid, ethylenediamine-N,N′-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), L-glutamic acid N,N-diacetic acid (GLDA), a salt thereof, or any combination thereof.

20. The LNP formulation of claim 1 , further comprising one or more therapeutic or prophylactic agents.

21. The LNP formulation of claim 20 , wherein the one or more therapeutic or prophylactic agents is a messenger ribonucleic acid (mRNA).

Assignees

• Modernatx Inc

Inventors

• Brader Mark

Classifications

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• C12N15/88

  using microencapsulation, e.g. using {amphiphile} liposome vesicle · CPC title

• A61K9/5123 Primary

  Organic compounds, e.g. fats, sugars · CPC title